Skip to content
GLP-1 Scorecard
Menu

Compare alternative providers

Alternatives to Zeuss

Zeuss grades C (65.8/100), #237 of 541 on our scorecard. Start with a featured alternative, then explore providers with similar listed prices and treatment options. Compare their scores and terms below.

You're comparing against

Zeuss →
Or visit Zeuss directly ↗

Featured alternative

CoreAge Rx scores 89.5/100. Check the price conditions and care terms against Zeuss.

CoreAge RxGraded #1Featured

Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Product page from $79/mo; navigation $99. Confirm selected quote. sema · From $129/mo advertised; confirm selected charge, supply and renewal. tirzUS only; therapy-specific state restrictions apply+23.7 vs Zeuss

More options to compare

Gimme CareGraded #15

Mid-value both-molecule pricing ($130/$163), verified, and nationwide.

$130/mo sema · $163/mo tirzAll 50 states+18.8 vs Zeuss
KongoGraded #19

Cheap semaglutide ($119) but a steeper tirzepatide step-up ($229); verified, nationwide.

$119/mo sema · $229/mo tirzAll 50 states+18 vs Zeuss
Fresh Day MedsGraded #18

Tight both-molecule spread ($133/$166), verified and nationwide.

$133/mo sema · $166/mo tirzAll 50 states+18.5 vs Zeuss

Low-ish both-molecule pricing ($117/$196), nationwide — but unverified.

$117/mo sema · $196/mo tirzAll 50 states+16.3 vs Zeuss
PiperGraded #31

Mid-value both-molecule pricing ($135/$199), nationwide, though not verified.

$135/mo sema · $199/mo tirzAll 50 states+16.1 vs Zeuss

The 6 alternatives above offer other options to compare with Zeuss. Every provider we grade — all 541 of them — is scored on the same six factors: browse every graded provider.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard